Would you like to participate ask a question join the surfers in our next episode?

S2-E37 – Why The NASH Market Is Different From Statins

Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets.

The group covers several important topics very quickly, with focus on pre-launch market development, testing metrics and why it matters which companies are coming to market first. One similarity: in the absence of approved medications, disease treatment rests heavily on improving healthy lifestyles, which is a challenging target no matter the disease

TOPICS: Diabetes, EchoSens, FibroScan, MRI-PDFF, NAFLD, NASH, Novo Nordisk, Testing, Hypercholesterolemia, pleiotropic effects, metabolic syndrome, statins, GLP-1s, MRE, statins, SGLT-2s, patient screening, patient subgroups

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request Transcript of This Episode
Request Transcript
First
Last

NASH & Diabetes Podcast and NASH Tsunami Podcast